These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18370855)

  • 1. ABCG2: structure, function and role in drug response.
    Polgar O; Robey RW; Bates SE
    Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of exploiting ABCG2 in the clinic.
    Robey RW; Ierano C; Zhan Z; Bates SE
    Curr Pharm Biotechnol; 2011 Apr; 12(4):595-608. PubMed ID: 21118093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
    Xu J; Peng H; Zhang JT
    Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
    Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCG2: a perspective.
    Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
    Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCG2: determining its relevance in clinical drug resistance.
    Robey RW; Polgar O; Deeken J; To KW; Bates SE
    Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
    Ejendal KF; Hrycyna CA
    Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
    Ni Z; Bikadi Z; Rosenberg MF; Mao Q
    Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCG2 -- a transporter for all seasons.
    Sarkadi B; Ozvegy-Laczka C; Német K; Váradi A
    FEBS Lett; 2004 Jun; 567(1):116-20. PubMed ID: 15165903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.
    Martín V; Sanchez-Sanchez AM; Herrera F; Gomez-Manzano C; Fueyo J; Alvarez-Vega MA; Antolín I; Rodriguez C
    Br J Cancer; 2013 May; 108(10):2005-12. PubMed ID: 23632480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic importance of ABCG2.
    Cusatis G; Sparreboom A
    Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
    Westover D; Li F
    J Exp Clin Cancer Res; 2015 Dec; 34():159. PubMed ID: 26714461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.